Is there a role for oral rapamycin in restenosis prevention after bare-metal stent implantation?
Jörg Hausleiter and Adnan Kastrati*
Correspondence *Deutsches Herzzentrum, Technische Universität, Lazarettstrasse 36, 80636 München, Germany
Email kastrati@dhm.mhn.de
This article has no abstract so we have provided the first paragraph of the full text.
The development of in-stent restenosis at the target lesion site through neointimal tissue proliferation is the main limitation of percutaneous coronary intervention with stenting. Although often considered a benign process, data suggest that in-stent restenosis development has a negative impact on long-term survival.1 Accordingly, major interest in the development of local and systemic strategies for in-stent restenosis prevention has followed.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
